VistaGen Therapeutics, Inc.
VTGN
$1.97
-$0.08-3.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -106.41% | 27.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -106.41% | 27.87% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -106.41% | 27.87% | |||
| SG&A Expenses | 5.53% | -3.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.69% | 6.55% | |||
| Operating Income | 4.13% | -6.28% | |||
| Income Before Tax | 3.22% | -8.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.22% | -8.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.22% | -8.70% | |||
| EBIT | 4.13% | -6.28% | |||
| EBITDA | 4.15% | -6.28% | |||
| EPS Basic | 5.82% | -8.41% | |||
| Normalized Basic EPS | 5.82% | -8.48% | |||
| EPS Diluted | 5.82% | -8.41% | |||
| Normalized Diluted EPS | 5.82% | -8.48% | |||
| Average Basic Shares Outstanding | 2.76% | 0.26% | |||
| Average Diluted Shares Outstanding | 2.76% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||